Notice convening extraordinary general meeting in NeuroSearch A/S

Announcement


Notice convening extraordinary general meeting in NeuroSearch A/S

Pursuant to article 10 of the Articles of Association, notice is hereby given
of the extraordinary general meeting of NeuroSearch A/S to be held on 

Friday, 21 December 2007 at 10.00 am

at the registered office of the Company, Pederstrupvej 93, DK-2750 Ballerup.
The agenda of the meeting is as follows: 

1. Authorisation to the Board of Directors to increase the Company's share
capital 

The Board of Directors proposes that Article 5 of the Articles of Association
be replaced by the following new Article 5 authorising the Board of Directors
to increase the Company's share capital: 

“During the period ending on 31 December 2011, the Board of Directors is
authorised to increase the Company's share capital in one or more issues of a
total nominal sum of up to DKK 76,000,000 (3,800,000 shares of DKK 20). 

The share capital may be increased by cash payment or by other means.

If the share capital is increased by cash payment at a subscription price lower
than the value of the shares, the existing shareholders are entitled to a right
of pre-emption in respect of the amount of the capital increase in proportion
to their shareholdings. 

If the share capital is increased by cash payment otherwise than specified in
Article 5(3), above, or is increased by other means, including by debt
conversion or in payment of a contribution of assets other than cash, the
Company's existing shareholders shall not be entitled to any right of
pre-emption. If the share capital is increased by other means than cash, the
provisions of section 33 of the Danish Companies Act (aktieselskabsloven) shall
apply, and the subscription price or the value of the shares issued shall be
fixed by the Board of Directors subject to the mandatory provisions of the Act,
including sections 79 and 80 thereof. 

All terms and conditions governing the subscription for shares shall be
stipulated by the Board of Directors. 

The new shares shall be negotiable instruments and shall be issued to bearer,
but the shares may be registered in the names of the holders in the Company's
register of shareholders. No restrictions shall apply to the transferability of
the new shares, and no shareholder shall be required to have his shares
redeemed in whole or in part. The shares shall carry the right to dividend as
from the date fixed by the Board of Directors but no later than from the first
financial year following the capital increase.” 

2. Any other business
 
The proposed resolution was adopted at the Company's extraordinary general
meeting on 10 December 2007 by more than two-thirds of all votes cast and of
the voting share capital represented at the extraordinary general meeting.
However, since less than one half of the share capital was represented at the
extraordinary general meeting the resolution could not be finally adopted.
Pursuant to Article 16 of the Company's Articles of Association, resolutions
passed by no less than two-thirds of the votes cast and of the voting share
capital represented at the extraordinary general meeting can be finally
adopted, if the resolutions are passed by no less than two-thirds of both the
votes cast and of the voting share capital represented at a new extraordinary
general meeting. 

Pursuant to Article 11 of the Articles of Association, all shareholders who
wish to attend the extraordinary general meeting must order admission cards via
www.neurosearch.com, from NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup
(telephone: +45 4460 8000 or telefax: +45 4460 8080) or from Aktiebog Danmark
A/S, Kongevejen 118, DK-2840 Holte (telephone: +45 4546 0999 or telefax: +45
4546 0998) no later than Thursday, 13 December 2007. All shareholders not
registered in the Company's register of shareholders who wish to attend the
extraordinary general meeting must establish good title to their shares by
presentation of documentation from their financial institute, such
documentation not to have been issued more than 14 days before the
extraordinary general meeting. The shareholders must also issue a statement in
writing to the effect that their shares have not been and will not be
transferred to any third party before the extraordinary general meeting. 


Asger Aamund
Chairman of the Board


Contact persons:
	
Flemming Pedersen, CEO, phone: +45 4460 8214 or +45 2148 0118

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, phone: +45 4460 8212 or +45 4017 5103 



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the Company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar
disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for
the treatment of various CNS diseases - both (Phase I) in collaboration with
Abbott as well as NSD-644 (Phase I) in collaboration with GSK. In addition,
NeuroSearch has a broad portfolio of preclinical drug candidates and holds
equity interests in several biotech companies.